Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: A novel strategy with potent efficacy in experimental liver fibrosis

Wang, 2014, The global burden of liver disease: the major impact of China, Hepatology, 60, 2099, 10.1002/hep.27406 Pinzani, 2015, Hepatic fibrosis: a global clinical problem, Stellate Cells Health Dis., 29, 10.1016/B978-0-12-800134-9.00003-8 Dobie, 2016, Homing in on the hepatic scar: recent advances in cell-specific targeting of liver fibrosis, F1000Research, 5, 1749, 10.12688/f1000research.8822.1 Ferrarese, 2016, Liver transplantation for viral hepatitis in 2015, World J. Gastroenterol., 22, 1570, 10.3748/wjg.v22.i4.1570 2017, Regression of liver fibrosis Yoneda, 2016, Vitamin A and insulin are required for the maintenance of hepatic stellate cell quiescence, Exp. Cell Res., 341, 8, 10.1016/j.yexcr.2016.01.012 Iredale, 2013, Extracellular matrix degradation in liver fibrosis: biochemistry and regulation, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1832, 876, 10.1016/j.bbadis.2012.11.002 Schon, 2016, Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis, Front. Pharmacol., 7, 33, 10.3389/fphar.2016.00033 Hayes, 2014, Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis, PLoS One, 9, e92925, 10.1371/journal.pone.0092925 Wagner, 2013, Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks, Sci. Signal., 6, ra58-ra, 10.1126/scisignal.2003994 Czochra, 2006, Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice, J. Hepatol., 45, 419, 10.1016/j.jhep.2006.04.010 Morphy, 2009, Selectively nonselective kinase inhibition: striking the right balance, J. Med. Chem., 53, 1413, 10.1021/jm901132v Qu, 2015, New insight into the anti-liver fibrosis effect of multitargeted tyrosine kinase inhibitors: from molecular target to clinical trials, Front. Pharmacol., 6, 300 Peng, 2005, Clinical pharmacokinetics of imatinib, Clin. Pharmacokinet., 44, 879, 10.2165/00003088-200544090-00001 Olivieri, 2009, Imatinib for refractory chronic graft-versus-host disease with fibrotic features, Blood, 114, 709, 10.1182/blood-2009-02-204156 Elmholdt, 2013, Anti-fibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial, J. Eur. Acad. Dermatol. Venereol., 27, 779, 10.1111/j.1468-3083.2011.04398.x Council NR, 1996 Dua, 2012, Liposome: methods of preparation and applications, Int. J. Pharm. Stud. Res., 3, 14 Ye, 2014, Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting, Int. J. Nanomedicine, 9, 2167, 10.2147/IJN.S60178 Sato, 2008, Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone, Nat. Biotechnol., 26, 431, 10.1038/nbt1396 Pereira, 2015, Cationic liposome-multi-walled carbon nanotubes hybrids for dual siPLK1 and doxorubicin delivery in vitro, Pharm. Res., 32, 3293, 10.1007/s11095-015-1707-1 El-Refaie, 2015, Novel curcumin-loaded gel-core hyaluosomes with promising burn-wound healing potential: development, in-vitro appraisal and in-vivo studies, Int. J. Pharm., 486, 88, 10.1016/j.ijpharm.2015.03.052 Patil, 2013, Development of UV-spectrophotometric method for the determination of Imatinib Mesylate (ITM) in bulk and formulation, Asian J. Pharm. Clin. Res., 6, 54 El-Refaie, 2015, Novel self-assembled, gel-core hyaluosomes for non-invasive management of osteoarthritis: in-vitro optimization, ex-vivo and in-vivo permeation, Pharm. Res., 32, 2901, 10.1007/s11095-015-1672-8 Ibrahim, 1991, Spectrophotometric assay of retinol via charge-transfer complexes, Microchim. Acta, 103, 209, 10.1007/BF01309027 Conrad, 2014, Identification of Quercus agrifolia (coast live oak) resistant to the invasive pathogen Phytophthora ramorum in native stands using Fourier-transform infrared (FT-IR) spectroscopy, Front. Plant Sci., 5, 521, 10.3389/fpls.2014.00521 Starkel, 2011, Animal models for the study of hepatic fibrosis, Best Pract. Res. Clin. Gastroenterol., 25, 319, 10.1016/j.bpg.2011.02.004 Kim, 2012, Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate, Liver Int., 32, 1008, 10.1111/j.1478-3231.2012.02806.x Alkharfy, 2013, Quantitative determination of imatinib stability under various stress conditions, J. Pharm. Bioallied Sci., 5, 49, 10.4103/0975-7406.106570 Teoh, 2010, HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice, Pak. J. Pharm. Sci., 23, 35 Bancroft, 2008 Ishak, 1994, Chronic hepatitis: morphology and nomenclature, Mod. Pathol., 7, 690 Goodman, 2007, Grading and staging systems for inflammation and fibrosis in chronic liver diseases, J. Hepatol., 47, 598, 10.1016/j.jhep.2007.07.006 Reitman, 1957, A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases, Am. J. Clin. Pathol., 28, 56, 10.1093/ajcp/28.1.56 Doumas, 1997, Albumin standards and the measurement of serum albumin with bromcresol green, Clin. Chim. Acta, 258, 21, 10.1016/S0009-8981(96)06447-9 Biggs, 1962 Fujimoto, 1993, A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies, Clin. Chim. Acta, 221, 91, 10.1016/0009-8981(93)90024-X Kropf, 1997, Immunological measurement of transforming growth factor-beta 1 (TGF-β1) in blood; assay development and comparison, Clin. Chem., 43, 1965, 10.1093/clinchem/43.10.1965 Woessner, 1961, The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid, Arch. Biochem. Biophys., 93, 440, 10.1016/0003-9861(61)90291-0 Kimura, 2008, Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation, Circulation, 118, S65, 10.1161/CIRCULATIONAHA.107.740613 Thampi, 2014, Indian J. Res. Pharm. Biotechnol., 2, 1082 Akagi, 2015, Delivery of imatinib-incorporated nanoparticles into lungs suppresses the development of monocrotaline-induced pulmonary arterial hypertension, Int. Heart J., 56, 354, 10.1536/ihj.14-338 Adrian, 2007, A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats, Biochim. Biophys. Biomembr., 1768, 1430, 10.1016/j.bbamem.2007.03.027 Li, 2012, Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor–beta on hepatic fibrosis in rats, J. Control. Release, 159, 261, 10.1016/j.jconrel.2011.12.023 Greupink, 2005, Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell, J. Hepatol., 43, 884, 10.1016/j.jhep.2005.04.014 Hagens, 2007, Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated, Pharm. Res., 24, 566, 10.1007/s11095-006-9175-2 Poosti, 2015, Selective delivery of IFN-γ to renal interstitial myofibroblasts: a novel strategy for the treatment of renal fibrosis, FASEB J., 29, 1029, 10.1096/fj.14-258459 Bansal, 2012, Selective targeting of interferon γ to stromal fibroblasts and pericytes as a novel therapeutic approach to inhibit angiogenesis and tumor growth, Mol. Cancer Ther., 11, 2419, 10.1158/1535-7163.MCT-11-0758 Prakash, 2010, A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier, J. Control. Release, 145, 91, 10.1016/j.jconrel.2010.03.018 Elnaggar, 2014, Lecithin-based nanostructured gels for skin delivery: an update on state of art and recent applications, J. Control. Release, 180, 10, 10.1016/j.jconrel.2014.02.004 Wen, 2016, Nanotechnology-based drug delivery systems for Alzheimer's disease management: technical, industrial, and clinical challenges, J. Control. Release, 245, 95, 10.1016/j.jconrel.2016.11.025 Azuma, 2007, Role of α1-acid glycoprotein in therapeutic anti-fibrotic effects of imatinib with macrolides in mice, Am. J. Respir. Crit. Care Med., 176, 1243, 10.1164/rccm.200702-178OC Li, 2015, Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro, Mol. Med. Rep., 12, 3453, 10.3892/mmr.2015.3842 Quadro, 1999, Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein, EMBO J., 18, 4633, 10.1093/emboj/18.17.4633 Quadro, 2004, The role of extrahepatic retinol binding protein in the mobilization of retinoid stores, J. Lipid Res., 45, 1975, 10.1194/jlr.M400137-JLR200 Wang, 2015, Diagnostic imaging and therapeutic application of nanoparticles targeting the liver, J. Mater. Chem. B, 3, 939, 10.1039/C4TB01611D Poelstra, 2012, Drug targeting to the diseased liver, J. Control. Release, 161, 188, 10.1016/j.jconrel.2012.02.011 Hernández-Caselles, 1993, Influence of liposome charge and composition on their interaction with human blood serum proteins, Mol. Cell. Biochem., 120, 119, 10.1007/BF00926084 Pereira-Lachataignerais, 2006, Study and formation of vesicle systems with low polydispersity index by ultrasound method, Chem. Phys. Lipids, 140, 88, 10.1016/j.chemphyslip.2006.01.008 Gubernator, 2011, Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity, Expert Opin. Drug Deliv., 8, 565, 10.1517/17425247.2011.566552 De Boeck, 1988, NMR study of the interaction of retinoids with phospholipid bilayers, Biochim. Biophys. Act Biomembr., 946, 244, 10.1016/0005-2736(88)90399-9 Wang, 2011, Recent advances of chitosan nanoparticles as drug carriers, Int. J. Nanomedicine, 6, 765 Kim, 2006, Retinol-encapsulated low molecular water-soluble chitosan nanoparticles, Int. J. Pharm., 319, 130, 10.1016/j.ijpharm.2006.03.040 Coates, 2000, Interpretation of infrared spectra, a practical approach Marty, 2009, Structural characterization of cationic lipid–tRNA complexes, Nucleic Acids Res., 37, 5197, 10.1093/nar/gkp543 Svensson, 2007, Retinoid chromophores as probes of membrane lipid order, J. Phys. Chem. B, 111, 10839, 10.1021/jp072890b Wassall, 1988, Electron spin resonance study of the interactions of retinoids with a phospholipid model membrane, Biochim. Biophys. Act Biomembr., 939, 393, 10.1016/0005-2736(88)90085-5 Noy, 1999, Physical-chemical properties and action of retinoids, 3 Hayashi, 2011, Animal models for the study of liver fibrosis: new insights from knockout mouse models, Am. J. Physiol. Gastrointest. Liver Physiol., 300, G729, 10.1152/ajpgi.00013.2011 AST, 2013 Wake, 2006, Hepatic stellate cells: three-dimensional structure, localization, heterogeneity and development, Proc. Jpn Acad. Ser. B, 82, 155, 10.2183/pjab.82.155 Seo, 2016, Hepatic non-parenchymal cells: master regulators of alcoholic liver disease?, World J. Gastroenterol., 22, 1348, 10.3748/wjg.v22.i4.1348 Fv, 2015, Targeted therapies in liver fibrosis: combining the best parts of platelet derived growth factor BB and interferon gamma, Front. Med., 2, 72 Gad, 2011 Cortes, 2016, Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: The ENRICH Study, Clin. Lymphoma Myeloma Leuk., 16, 286, 10.1016/j.clml.2016.02.002 Darkow, 2007, Treatment interruptions and non-adherence with imatinib and associated healthcare costs, PharmacoEconomics, 25, 481, 10.2165/00019053-200725060-00004 Steegmann, 2012, Off-target effects of BCR–ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia, Leuk. Lymphoma, 53, 2351, 10.3109/10428194.2012.695779 Chambers, 2017, Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity, Toxicology, 382, 24, 10.1016/j.tox.2017.03.006 Peerzada, 2011, Pulmonary toxicities of tyrosine kinase inhibitors, Clin. Adv. Hematol. Oncol., 9, 824 Spiekermann, 2016, Therapeutic management of acute lymphoblastic leukemia, 65 Kruk, 2013, Transactivation of platelet-derived growth factor receptor type β: mechanisms and potential relevance in, Neurobiology, 5 Contreras-Zentella, 2015, liver enzyme release really associated with cell necrosis induced by oxidant stress?, Oxidative Med. Cell. Longev., 2016, 1, 10.1155/2016/3529149 Salman, 2016, New era for usage of serum liver enzymes as a promising horizon for the prediction of non-alcoholic fatty liver disease, Open Access Macedonian J. Med. Sci., 4, 348, 10.3889/oamjms.2016.092 Giannini, 2005, Liver enzyme alteration: a guide for clinicians, Can. Med. Assoc. J., 172, 367, 10.1503/cmaj.1040752 Qu, 2016, Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?, Oncotarget, 7, 67650, 10.18632/oncotarget.11767 Ridruejo, 2007, Imatinib-induced fatal acute liver failure, World J. Gastroenterol., 13, 6608, 10.3748/wjg.v13.i48.6608 Shaker, 2011, Comparison of early treatment with low doses of nilotinib, imatinib and a clinically relevant dose of silymarin in thioacetamide-induced liver fibrosis, Eur. J. Pharmacol., 670, 593, 10.1016/j.ejphar.2011.08.041 Kim, 2012, Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate, Liver Int., 32, 1008, 10.1111/j.1478-3231.2012.02806.x Zhang, 2015, Potent effects of dioscin against liver fibrosis, Sci Rep, 5, 9713, 10.1038/srep09713 Gressner, 2002, Roles of TGF-beta in hepatic fibrosis, Front. Biosci., 7, d793, 10.2741/A812 Duarte, 2015, Matrix metalloproteinases in liver injury, repair and fibrosis, Matrix Biol., 44, 147, 10.1016/j.matbio.2015.01.004 Yang, 2007, Establishment of an early liver fibrosis model by the hydrodynamics-based transfer of TGF-β1 gene, Comp. Hepatol., 6, 9, 10.1186/1476-5926-6-9 Gressner, 2007, Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options, Comp. Hepatol., 6, 7, 10.1186/1476-5926-6-7 Breitkopf, 2001, Expression and matrix deposition of latent transforming growth factor β binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture, Hepatology, 33, 387, 10.1053/jhep.2001.21996 Takahara, 1997, Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers, Hepatology, 26, 1521, 10.1002/hep.510260620